Shionogi Europe Revenue and Competitors

UK

Location

N/A

Total Funding

Pharma

Industry

Estimated Revenue & Valuation

  • Shionogi Europe's estimated annual revenue is currently $50.9M per year.(i)
  • Shionogi Europe's estimated revenue per employee is $201,000

Employee Data

  • Shionogi Europe has 253 Employees.(i)
  • Shionogi Europe grew their employee count by 25% last year.

Shionogi Europe's People

NameTitleEmail/Phone
1
VP, Head Supply Chain and Strategy PlanningReveal Email/Phone
2
SVP, Regulatory Affairs EUReveal Email/Phone
3
Director, Risk Management, Clinical DevelopmentReveal Email/Phone
4
Senior Manager, Clinical Quality (Good Clinical Practice / Good Pharmacovigilance Practice)Reveal Email/Phone
5
Senior IT Manager, EuropeReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$58.9M2936%N/AN/A
#2
$21.1M1055%N/AN/A
#3
$113.4M5641%N/AN/A
#4
$20.9M104-5%N/AN/A
#5
$37M1849%N/AN/A
#6
$45.4M226-24%N/AN/A
#7
$16.1MN/AN/AN/A
#8
$69.7M3470%N/AN/A
#9
$8M403%N/AN/A
#10
$25.5M12728%N/AN/A
Add Company

What Is Shionogi Europe?

About Shionogi Shionogi was founded in 1878 in Osaka, Japan where our headquarters remain. The company has grown to become a major research-driven pharmaceutical company dedicated to placing the highest value on patient care. Shionogi has a strong heritage in the discovery and development of globally important therapies. Shionogi & Co., Ltd launched it's European Headquarters, Shionogi Limited in London in 2012. Establishing the new headquarters is an important milestone for the Company as it further expands the organisation into the global arena. Shionogi Limited will serve as a hub for development and drive the management of new innovative medicines across Europe, as well as the Middle East and Africa. Shionogi Limited aspires to be at the forefront of areas within our focus and push the boundaries of science and the way we work.

keywords:N/A

N/A

Total Funding

253

Number of Employees

$50.9M

Revenue (est)

25%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Shionogi Europe News

2022-04-19 - Pfizer's Covid Pill Is Poised to Be Among the Fastest-Selling Treatments of All Time

Sales of pills from Merck & Co. and Shionogi & Co. are also set to ... Wealthy countries led by the U.S., U.K. and Europe are driving the...

2022-04-13 - UK bid to battle antibiotic resistance yields first subscription ...

... from Shionogi and ceftazidime–avibactam from Pfizer for subscription-style purchasing. The former drug is sold as Fetcroja in Europe and...

2022-03-30 - Vaxxas strikes deal to tee up trial of COVID-19 vaccine patch

Still, Sandoz's sales declined in both Europe and the U.S. in 2021 no thanks to pricing pressures. Worldwide, the unit's 2021 sales dropped 2% at constant...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$54.9M253-2%$55.8M
#2
$40.4M25330%N/A
#3
$50.1M2532%N/A
#4
$75.1M2537%N/A
#5
$68.2M253-5%N/A